04:11 PM EDT, 08/21/2019 (MT Newswires) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company, saw its shares jump more than 10% on Wednesday, then after trade it announced that the China National Intellectual Property Administration (CNIPA, formerly SIPO) issued a Notice to Undergo Registration Procedures and a Notice to Grant Patent Rights for a Chinese patent application for the company's platform technology.

According to a statement, the patent application relates to Bioasis' P97 conjugates with therapeutic agents where P97 has the ability to transport the agent across the blood-brain barrier (BBB).

Koo